InsidersTradesSigma
Follow the Terns Pharmaceuticals, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Terns Pharmaceuticals, Inc. has logged 58 public disclosures. Market capitalisation: €1,040.1bn. The latest transaction was filed on 2 April 2026 (Cession). Among the most active insiders: Vignola Mark J.. Every trade is free.
58
Insider Decl.
n/a
Thresholds
€37m
30 ops.
Buy Volume
€7m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Terns Pharmaceuticals, Inc. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,507.38.
59Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,265 of 29,062 companies
52.5
score / 100
Value27
Quality79
FCF yld0.2%
Earn yld0.9%
EV/EBITDA51.0x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 April 2026
Declarations58 total
942 shares@ US$52.752661.4% of flowCommon StockSEC:0001892413-26-000006:0
14,583 shares@ US$4.6424.3% of flowCommon StockSEC:0001872564-26-000008:0
14,583 shares@ US$4.6414.8% of flowCommon StockSEC:0001872564-26-000006:0
56,250 shares0Common StockSEC:0001892413-26-000004:0
150,000 shares0Common StockSEC:0001872564-26-000004:0
68,750 shares0Common StockSEC:0001563623-26-000002:0
21,551 shares@ US$4.6422.0% of flowCommon StockSEC:0001872564-26-000002:0
200 shares@ US$39.607.8% of flowCommon StockSEC:0001892413-26-000002:0
24,520 shares@ US$9.2460.1% of flowCommon StockSEC:0001799780-25-000004:0
944 shares@ US$7.84648.0% of flowCommon StockSEC:0001892413-25-000004:0
853 shares@ US$4.26714.2% of flowCommon StockSEC:0001562180-25-005308:0
5,000 shares@ US$3.926751.0% of flowCommon StockSEC:0001562180-25-005120:0
Canonical exit: 25 Sept 2025 (T+90)
23,314 shares@ US$3.870241.8% of flowCommon StockSEC:0001562180-25-005077:0
Canonical exit: 23 Sept 2025 (T+90)
5,000 shares@ US$3.75100.0% of flowCommon StockSEC:0001562180-25-004866:0
Canonical exit: 11 Sept 2025 (T+90)
952 shares@ US$2.48518.1% of flowCommon StockSEC:0001562180-25-002920:0
2,250 shares@ US$5.11100.0% of flowCommon StockSEC:0001562180-25-000853:0
Canonical exit: 28 Feb 2025 (T+90)
510 shares@ US$5.112.3% of flowCommon StockSEC:0001562180-25-000851:0
Canonical exit: 28 Feb 2025 (T+90)
8,129 shares@ US$5.723232.2% of flowCommon StockSEC:0001562180-25-000220:0
6,240 shares@ US$5.721526.4% of flowCommon StockSEC:0001562180-25-000219:0
4,481 shares@ US$5.714691.9% of flowCommon StockSEC:0001562180-25-000221:0
15,450 shares@ US$7.1597.7% of flowCommon StockSEC:0001562180-24-008254:0
Canonical exit: 5 Mar 2025 (T+90)
10,000 shares@ US$5.3634.9% of flowCommon StockSEC:0001562180-24-006794:0
17,235 shares@ US$1.8221.8% of flowCommon StockSEC:0001562180-24-006776:0
6,143 shares@ US$7.675133.5% of flowCommon StockSEC:0001562180-24-006019:0
25 of 58 declarations
Acerca de Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades metabólicas y hepáticas. Cotiza en NASDAQ bajo el símbolo TERN.